StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”). While the results showed overall improvement in patients treated with the Company’s proprietary cells, the magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available to the Company.

READ THE FULL GLOBE NEWSWIRE STORY AT THIS LINK

The Niche: End of line for StemCells Inc., pioneering & controversial stem cell biotech:

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Stem Cell Research and tagged . Bookmark the permalink.